Article

Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 prospective phase 2 trial

2020-06-05

Abstract excerpt

<h4>Background</h4> Tocilizumab blocks pro-inflammatory activity of interleukin-6 (IL-6), involved in pathogenesis of pneumonia the most frequent cause of death in COVID-19 patients. <h4>Methods</h4> A multicentre, single-arm, hypothesis-driven phase 2 trial was planned to study the effect of Tocilizumab on lethality rates at 14 and 30 days (co-primary endpoints). A cohort of patients consecutively enrolled after...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3c047308-72b8-57f6-b121-f2dcf178a3e6
DOI: 10.1101/2020.06.01.20119149

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Tocilizumab for patients with COVID-19 pneumonia. The TOCIVID-19 prospective phase 2 trialDOI 10.1101/2020.06.01.20119149Read

Tocilizumab treatment leads to early resolution of lymphopenia and myeloid dysregulation in patients hospitalized with COVID-19Semantic proximity Read

Timely Administration of Tocilizumab Improves Survival of Hospitalized COVID-19 PatientsSemantic proximity Read

A systematic review and meta-analysis of Anakinra, Sarilumab, Siltuximab and Tocilizumab for Covid-19Semantic proximity Read

Tocilizumab, netakimab, and baricitinib in patients with mild-to-moderate COVID-19: a retrospective cohort studySemantic proximity Read

Tocilizumab Efficacy Across Inflammatory Subphenotypes in COVID-19-Related Acute Respiratory Distress Syndrome.Semantic proximity Read

Tocilizumab versus sarilumab among adults hospitalised with COVID-19: target trial emulation across England and ScotlandSemantic proximity Read

A two-arm, randomized, controlled, multi-centric, open-label Phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19Semantic proximity Read

Early suPAR-Guided Anakinra Treatment in COVID-19 Pneumonia: Subgroup Analyses and 90-Day Outcomes of the SAVE-MORE TrialSemantic proximity Read

Single Versus Multiple Doses of Tocilizumab in Critically Ill Patients with Coronavirus Disease 2019 (COVID-19): A Two-center, Retrospective Cohort StudySemantic proximity Read

Making sense of non-randomized comparative treatment studies in times of Covid-19: A case study of tocilizumabSemantic proximity Read

Mortality Predictors Of Pre-variant SARS-CoV-2 Infected ARDS Patients Receiving Favipiravir and TocilizumabSemantic proximity Read

Course of inflammation and infection markers differ in ICU patients with severe COVID-19 under casirivimab- and/or tocilizumab application: an observational studySemantic proximity Read